研究单位：[1]Betta Pharmaceuticals Co.,Ltd.[2]Xuanwu Hospital,Capital Medical University
研究目的：
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.
